Visit https://www.peervoice.com/THS860 to view the entire programme with slides. After completing “Colin Russell, PhD / John Watkins, MBBCh, BSc - A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact”, participants will be able to: Recognise the evolving epidemiology and overlapping seasonality of COVID-19 and influenza, and understand how these factors impact vaccine strategies - particularly in managing coinfections, waning immunity, and emerging variants; Understand the latest evidence and data on how combination vaccines could simplify immunisation schedules, improve compliance, and may enhance vaccine uptake across COVID-19 and influenza, while demonstrating comparable efficacy and safety to standalone vaccines; and Describe how mRNA platforms enable the development of combination vaccines, including their programmability, precision targeting, scalability, and role in overcoming formulation challenges.

Visit https://www.peervoice.com/JBN860 to view the entire programme with slides. After completing “Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition”, participants will be able to: Describe recent data updates from clinical trials and studies examining approved therapies in the management of C3G and IC-MPGN; Appraise the clinical significance of the data in the context of real-world evidence relating to outcomes across different patient populations with C3G and IC-MPGN; and Utilize available data to facilitate treatment decision-making in the management of C3G and IC-MPGN.

Visit https://www.peervoice.com/EPK860 to view the entire programme with slides. After completing “Erwan Donal, MD, PhD / Nina Ajmone Marsan, MD, PhD - At the Cutting Edge of ATTR-CM: How Can We Leverage Advances in Multimodality Cardiac Imaging and Artificial Intelligence to Modernise Diagnosis and Monitoring?”, participants will be able to: Evaluate the strengths and limitations of multimodality cardiac imaging within the evolving diagnostic landscape of transthyretin amyloid cardiomyopathy (ATTR-CM); Assess the role and applications for multimodality cardiac imaging in monitoring treatment efficacy and disease progression in ATTR-CM; and Identify current and potential future applications of artificial intelligence in multimodality imaging in ATTR-CM.

Visit https://www.peervoice.com/KFX860 to view the entire programme with slides. After completing “Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: Breaking Down the Data Driving Therapeutic Developments in IgA Nephropathy”, participants will be able to: Recall recent efficacy and safety trial data on new and emerging therapies in IgA nephropathy (IgAN); and Assess recent therapeutic developments in the context of proposed KDIGO recommended treatment targets in the management of IgAN.

Visit https://www.peervoice.com/QXH860 to view the entire programme with slides. After completing “Jonathan Barratt, PhD, FRCP - 2025 Congress Highlights From Houston, Texas: A Fresh Look at the Data Driving Targeted Therapeutic Developments in IgA Nephropathy”, participants will be able to: Describe the safety and efficacy data, including key endpoints, from trials examining novel B-cell modulator therapies in IgA nephropathy (IgAN); and Appraise the clinical data from recent therapeutic developments, including B-cell modulators, in the context of updated KDIGO recommended treatment targets and approved therapies in the management of IgAN.

Visit https://www.peervoice.com/YZQ860 to view the entire programme with slides. After completing “Nancy Carteron, MD, FACR - Congress Insights Direct From Chicago: The Need-to-Knows on B Cell–Targeting in Sjögren’s Disease”, participants will be able to: Summarise recently presented clinical trial data evaluating novel therapies in the management of patients with Sjögren’s disease; and Analyse recent evidence on B cell–mediated pathophysiological mechanisms in Sjögren’s disease.

Visit https://www.peervoice.com/GKA860 to view the entire programme with slides. After completing “James F. Howard Jr, MD - Direct From San Francisco: Emerging Data and Expert Perspectives on Targeted Therapies for gMG”, participants will be able to:

Visit https://www.peervoice.com/VZW860 to view the entire programme with slides. After completing “Mike Sharma, MD, MSc, FRCPC - Challenging the Status Quo in Secondary Stroke Prevention: Current Perspectives on the Potential of Factor XIa Inhibition”, participants will be able to: Recognise the limitations of traditional strategies for secondary stroke prevention following noncardioembolic stroke or transient ischaemic attack (TIA); Recall the pathophysiologic rationale for use of factor XIa inhibitors in secondary stroke prevention; and Evaluate the design and methods of phase 3 trials of factor XIa inhibitors for the prevention of ischaemic stroke following acute noncardioembolic ischaemic stroke or high-risk TIA.

Visit https://www.peervoice.com/PHJ860 to view the entire programme with slides. After completing “David Alain Wohl, MD - Inpatient Management of SARS-CoV-2 Infection: Applying Learnings From Real World Evidence to Real World Practice”, participants will be able to: Discuss current inpatient management guidelines for patients with SARS-CoV-2 infection; Evaluate the impact of emerging SARS-CoV-2 variants on therapeutic efficacy; Assess the data from real-world studies of the potential impact of established treatments on clinical outcomes including long COVID; Evaluate which patients with SARS-CoV-2 infection are at risk of progression to severe disease; and Propose evidence-based effective therapeutic approaches for the management of hospitalised patients with SARS-CoV-2 infection based on risk evaluation and in context of updated treatment strategies.

Visit https://www.peervoice.com/FMW860 to view the entire programme with slides. After completing “Emer Joyce, MB BCh BAO, PhD - Staying Ahead of the Curve in ATTR-CM: Adapting and Advancing Our Approach to Decision-Making as the Treatment Landscape Evolves”, participants will be able to: Assess available data which may be applied to guide treatment decision-making within the evolving treatment landscape of transthyretin amyloid cardiomyopathy (ATTR-CM); Differentiate between TTR stabilisers based on existing evidence in ATTR-CM; and Apply current evidence related to the use of combination therapy in patients with ATTR-CM.

Visit https://www.peervoice.com/XSX860 to view the entire programme with slides. After completing “Alice M. Turner, MBChB, PhD - Cross-Talk Between Lung and Liver in Alpha-1 Antitrypsin Deficiency: A Call for Integrated Care”, participants will be able to: Apply current guideline recommendations for timely testing and screening for alpha-1 antitrypsin deficiency (AATD) to facilitate early diagnosis and interventions; Identify best practices and practical strategies for the collaborative monitoring and management of patients with AATD; and Assess the phase 3 landscape of investigational therapies for the treatment of liver disease associated with AATD.

Visit https://www.peervoice.com/HQU860 to view the entire programme with slides. After completing “Patrick Vermersch, MD, PhD - Stripped Back: CNS Inflammation and the Potential for Meaningful Therapeutic Progress in Non-Relapsing Forms of Multiple Sclerosis”, participants will be able to: Recognise the unmet needs and limitations of current treatment approaches in addressing disability and disease progression in patients with non-relapsing forms of multiple sclerosis (MS); Describe the mechanistic rationale for emerging therapies (eg, Bruton tyrosine kinase inhibitors [BTKi] and anti-CD40 ligand [CD40L] monoclonal antibodies) in the context of the pathophysiological drivers of central nervous system inflammation in primary progressive and non-relapsing secondary progressive MS; Discuss the design and patient populations associated with clinical trials examining emerging therapies in primary progressive and non-relapsing and secondary progressive MS; and Appraise the data from trials examining the safety and efficacy of emerging therapies (eg, BTKi and anti-CD40L monoclonal antibodies) in primary progressive and non-relapsing secondary progressive MS.

Visit https://www.peervoice.com/UQF860 to view the entire programme with slides. After completing “Jonathan Barratt, PhD, FRCP - Preserve and Prevent: Expert Perspectives on Optimizing Outcomes in Patients With IgAN”, participants will be able to: Utilize evidence-based approaches to stratify risk and guide treatment decisions in patients with IgA nephropathy (IgAN); Appraise efficacy and safety data from pivotal clinical trials evaluating recently approved therapies for IgAN; Recognize practical considerations for the use of recently approved therapies used in the management of IgAN; and Establish evidence-based treatment strategies to optimize outcomes in the management of IgAN.

Visit https://www.peervoice.com/ZUC860 to view the entire programme with slides. After completing “Solange Peters, MD, PhD - Pioneering Precision: A Real-World Roadmap to Optimal Outcomes in NTRK Fusion-Positive and HER2-Mutant Advanced NSCLC”, participants will be able to: Utilise appropriate diagnostic technologies to overcome challenges in accurately characterising molecular alterations in patients with NTRK fusion-positive and HER2-mutant advanced NSCLC; Differentiate between precision oncology therapies used in patients’ management of NTRK fusion-positive advanced NSCLC; Distinguish between the study populations of clinical trials examining emerging targeted therapies in patients with advanced NSCLC harbouring HER2-activating mutations from studies examining other HER2 aberrations; and Describe the recent data and clinical significance associated with trials examining emerging targeted therapies in patients with advanced NSCLC harbouring HER2-activating mutations.

Visit https://www.peervoice.com/MYY860 to view the entire programme with slides. After completing “Vijay Ramaswamy, MD, PhD, FRCPC / Sébastien Perreault, MD, FRCPC / Lucie Lafay-Cousin, MD - Spot, Act, and Treat: Canadian Consensus Updates on Neurofibromatosis Type 1-Associated Plexiform Neurofibromas”, participants will be able to: Identify strategies to streamline referral for patients with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) in the Canadian landscape; Evaluate consensus-based approaches for managing patients with NF1-associated PN across the continuum of care; and Support strategies to ensure effective transition from pediatric to adult care for patients with NF1-associated PN.

Visit https://www.peervoice.com/THB860 to view the entire programme with slides. After completing “Amber S. Podoll, MD, FASN - Stepping Up Kidney Protection in Patients With Lupus Nephritis: When and How?”, participants will be able to: Recall therapeutic recommendations for the optimal management of class III/IV lupus nephritis as outlined in the KDIGO and/or EULAR guideline; Evaluate the impact of established and emerging biologic therapies on kidney outcomes and preservation of renal function in patients with lupus nephritis; and Assess patient characteristics and clinical features of lupus nephritis to determine an evidence-based treatment approach that has the potential to optimise renal outcomes for patients with class III/IV disease.

Visit https://www.peervoice.com/HCJ860 to view the entire programme with slides. After completing “Jonathan Barratt, PhD, FRCP - The Gut–Kidney Axis and Beyond in IgA Nephropathy: A New Frontier in Precision Therapy”, participants will be able to: Explain the pathophysiological significance of the gut–kidney axis in IgA nephropathy (IgAN), including the rationale for targeting the mucosal immune system; Appraise the data from clinical trials examining the safety and efficacy of new therapies in the management of IgAN; and Evaluate data associated with approved therapies, in the context of proposed KDIGO recommended treatment targets and approved therapies, in the management of IgAN.

Visit https://www.peervoice.com/NUF860 to view the entire programme with slides. After completing “Eva Diehl - Wiesenecker, MD - Rare Causes of Abdominal Pain: Differential Diagnosis of Uncommon but Diagnosable Causes in the Emergency Room”, participants will be able to: Discuss the impact of delayed and/or misdiagnosis of a rare cause of abdominal pain on patients and healthcare systems; Recognise the clinical features that would increase suspicion of a rare cause of abdominal pain; and Apply appropriate diagnostic algorithms for patients who present to the emergency room with severe abdominal pain and in whom the findings from a typical work-up are inconclusive.

Visit https://www.peervoice.com/CAX860 to view the entire programme with slides. After completing “Alberto Ortiz, MD, PhD - Rare, Complex, and Life-Threatening: Recognizing and Responding to Atypical Hemolytic Uremic Syndrome”, participants will be able to: Describe the pathophysiology of atypical hemolytic uremic syndrome (aHUS), including the involvement of terminal complement dysregulation and how this impacts renal function; Assess the clinical significance of clinical trial data and real-world evidence evaluating the use of complement component C5 inhibitors in managing aHUS; Implement evidence-based best practices for the timely recognition and diagnosis of aHUS in patients who present with symptoms of this condition; and Formulate appropriate, individualized approaches to managing aHUS in patients presenting for first-line treatment or experiencing relapse after treatment discontinuation.

Visit https://www.peervoice.com/YYK860 to view the entire programme with slides. After completing “Jonathan Barratt, PhD, FRCP - The Nephrology Journal Club: B-Cell Modulators and eGFR Endpoints in IgA Nephropathy”, participants will be able to: Recall the safety data from trials examining novel B-cell modulator therapies in IgA nephropathy; Describe the efficacy data from trials examining novel B-cell modulator therapies in IgA nephropathy; and Appraise the clinical evidence from recent therapeutic developments, including B-cell modulators, in the context of proposed KDIGO recommended treatment targets (eg, eGFR) and approved therapies in the management of IgA nephropathy.